Jianfeng Group Pro 2017-0112016 Annual General Meeting Resolution Announcement
Release time:
2020-08-05
Zhejiang Jianfeng Group Co., Ltd.
2016 Annual General Meeting Resolution Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents. |
Important Content Reminder:
l Whether there is a Resolution at this Meeting: No
1. Meeting and Attendance
(I) Shareholders' Meeting Time: May 19 , 2017
(II) Shareholders' Meeting Place: Conference Room, 3rd Floor, Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
(III) Common Shareholders and Preferred Shareholders with Restored Voting Rights present at the meeting and their shareholdings:
1 , number of shareholders and agents attending the meeting |
6 |
2 , total number of voting shares (shares) held by shareholders attending the meeting |
55,604,815 |
3 , the proportion of voting shares held by shareholders attending the meeting to the total voting shares of the company (% ) |
16.16 |
(IV) whether the voting method conforms to the provisions of the Company Law and the Articles of Association of the Company, presiding at the General Assembly, etc.
This meeting was held and voted by a combination of on-site voting and online voting. The meeting was convened by the company's board of directors , chaired by Mr. Jiang Xiaomeng. The convening of the meeting, held in accordance with the relevant laws, regulations, rules and the provisions of the articles of association of the company.
Attendance of Directors, Supervisors and Board Secretary of (V) Company
, Company has 8 current directors and 5 present. Chairman Jiang Xiaomeng, Directors Yu Jianhong, Wu Guanghui, Independent Directors Shi Ximin and Huang Congyun attended the meeting. Directors Du Zihong, Zhu Linming and Independent Director Sun Hongbin were unable to attend the meeting due to business trip;
, Company has 4 incumbent supervisors and 4 attendees, all supervisors attended the meeting; Zhu Jianwei, secretary of the board of directors of
3 and Company, attended the meeting. Deputy general managers of the company, Huang Jinlong, Zhang Fengliang, Xiang Chongping and financial officer Lan Xiaolong, attended the meeting as nonvoting delegates.
2. Proposal Review
(I) Non-cumulative Voting Proposal
1, Proposal Name: 2016 Board of Directors Work Report
Review Results: Passed
Voting:
Shareholder Type |
Agree |
Oppose |
Abstention |
|||
Votes |
Proportion (% ) |
Votes |
ratio (% ) |
votes |
ratio (% ) |
|
A shares |
55,602,815 |
99.9964 |
2,000 |
0.0036 |
0 |
0.0000 |
, Bill Name:
2016 Board of Supervisors Work ReportReview Results:
PassedVoting:
Shareholder Type |
Agree |
Oppose |
Abstention |
|||
Votes |
Proportion (% ) |
Votes |
ratio (% ) |
votes |
ratio (% ) |
|
A shares |
55,602,815 |
99.9964 |
2,000 |
0.0036 |
0 |
0.0000 |
, Proposal Name:
2016Annual Financial Statement Report
Review Results:Passed
Proportion (% | )
ratio (% | )
ratio (% | )
||||
A | shares
||||||
,
Bill Name:2016 Annual Profit Distribution Proposal
Review Results:
passed
| Shareholder Type |
Agree |
Oppose |
||||
| Votes | Proportion (%
) |
Votes | ratio (%
) |
votes | ratio (%
||
| shares |
55,602,815 |
99.9964 |
2,000 |
0.0036 |
0 |
|
,
Proposal Name:# Proposal 509 Hiring CompanyAudit Institution for 2017
Review Results:
Passed
| Shareholder Type |
Agree |
Oppose |
||||
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page